Aeglea Biotherapeutics appoints Jonathan Alspaugh as CFO effective July 6, 2021

Spyre Therapeutics, Inc.

Jonathan Alspaugh (38) named CFO; was Managing Director at Evercore's Corporate Advisory business from April 2013 to June 2021.
Annual base salary of $400,008; eligible for cash bonus up to 40% of base salary based on performance criteria.
Granted option to purchase 160,000 shares of common stock at closing price on July 6, 2021.
Option vests 1/4th after one year and 1/48th monthly thereafter, subject to continued service.
Company entered standard indemnification agreement with Alspaugh.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jonathan Alspaugh

Chief Financial Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2021-07-06
Filed: July 8, 2021, 7:59 PM ET

On June 23, 2021, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jonathan Alspaugh, age 38, as Chief Financial Officer, effective July 6, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Alspaugh was appointed as Chief Financial Officer at Spyre Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 23, 2021, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jonathan Alspaugh, age 38, as Chief Financial Officer, effective July 6, 2021.

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-036032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.